Table 1.
Baseline patient and tumor characteristics
| Characteristics | All patients (n = 57) |
|---|---|
| Age (years) (mean ± SD) | 57 ± 10.6 |
| Gender, female (%) | 39 (68.4) |
| Smoking status | |
| Never | 41 (71.9) |
| Ever | 16 (28.1) |
| ECOG performance status | |
| 0 | 6 (10.5) |
| 1 | 49 (86) |
| 2 | 2 (3.5) |
| EGFR mutation by tissue biopsy | |
| Exon 19 del | 39 (68.4) |
| L858R | 18 (31.6) |
| Stage | |
| M0/< M1a | 23 (40.4) |
| M1b | 34 (59.6) |
| TKI | |
| Gefitinib | 55 (96.5) |
| Erlotinib | 1 (1.8) |
| Afatinib | 1 (1.8) |
| Best response | |
| Partial response | 44 (77.2) |
| Stable disease | 12 (21.1) |
| Progressive disease | 1 (1.8) |
Unless otherwise stated, data are presented as number (%).ECOG, Eastern Cooperative Oncology Group; SD, standard deviation; TKI, tyrosine kinase inhibitor.